Cellply has obtained a grant by the European Commission to support its R&D program. It is the largest one among the nine Italian companies funded in the last SME Instrument call and one of the largest at EU level since the start of the SME Instrument program in 2014. This will provide the resources to complete the development of an innovative diagnostic platform.
Cellply, based in Bologna, Italy, was founded in 2013 by two engineers, Professor Roberto Guerrieri from the University of Bologna and Massimo Bocchi. It is a medtech start-up company specialized in in vitro diagnostic systems aiming at supporting personalized oncology treatments. In 2014, the company started the development of an in vitro diagnostic platform which enabled the isolation of a tiny amount of live tumor cells sampled from patients within 20,000 microwells and to analyze the action of multiple drugs in parallel by means of proprietary algorithms to predict the response of the patient to candidate drug therapies.
Oaklins' team in Italy successfully assisted Cellply along the entire fundraising process.
© 2019 Oaklins. All rights reserved. Oaklins is the collective trade name of independent member firms affiliated with Oaklins International Inc. For details of the nature of affiliation, please refer to www.oaklins.com/legal.